120 related articles for article (PubMed ID: 16368922)
21. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
22. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
23. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women.
O'Connell MB; Frye RF; Matzke GR; St Peter JV; Willhite LA; Welch MR; Kowal P; LaValleur J
J Clin Pharmacol; 2006 Nov; 46(11):1299-307. PubMed ID: 17050794
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress.
Leclercq I; Desager JP; Horsmans Y
Clin Pharmacol Ther; 1998 Aug; 64(2):144-9. PubMed ID: 9728894
[TBL] [Abstract][Full Text] [Related]
25. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
26. Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Zgheib NK; Frye RF; Tracy TS; Romkes M; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):257-63. PubMed ID: 16952492
[TBL] [Abstract][Full Text] [Related]
27. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Peterson GM; Naunton M; Tichelaar LK; Gennari L
Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
[TBL] [Abstract][Full Text] [Related]
28. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
Chen R; Wang H; Shi J; Hu P
Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
[TBL] [Abstract][Full Text] [Related]
29. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.
Ernstgård L; Warholm M; Johanson G
Br J Clin Pharmacol; 2004 Aug; 58(2):190-200. PubMed ID: 15255802
[TBL] [Abstract][Full Text] [Related]
30. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Frye RF; Tammara B; Cowart TD; Bramer SL
J Clin Pharmacol; 1999 Nov; 39(11):1177-83. PubMed ID: 10579149
[TBL] [Abstract][Full Text] [Related]
31. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
Davies BJ; Coller JK; James HM; Gillis D; Somogyi AA; Horowitz JD; Morris RG; Sallustio BC
Br J Clin Pharmacol; 2004 Apr; 57(4):456-63. PubMed ID: 15025744
[TBL] [Abstract][Full Text] [Related]
32. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
[TBL] [Abstract][Full Text] [Related]
33. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
[TBL] [Abstract][Full Text] [Related]
34. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
35. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Asimus S; Elsherbiny D; Hai TN; Jansson B; Huong NV; Petzold MG; Simonsson US; Ashton M
Fundam Clin Pharmacol; 2007 Jun; 21(3):307-16. PubMed ID: 17521300
[TBL] [Abstract][Full Text] [Related]
36. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Dickinson GL; Rezaee S; Proctor NJ; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2007 Feb; 47(2):175-86. PubMed ID: 17244768
[TBL] [Abstract][Full Text] [Related]
37. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation.
Burckart GJ; Frye RF; Kelly P; Branch RA; Jain A; Fung JJ; Starzl TE; Venkataramanan R
Clin Pharmacol Ther; 1998 Mar; 63(3):296-302. PubMed ID: 9542473
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene.
Haufroid V; Buchet JP; Gardinal S; Lison D
Int Arch Occup Environ Health; 2002 Sep; 75(7):453-8. PubMed ID: 12172891
[TBL] [Abstract][Full Text] [Related]
39. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
Serra DB; Affrime MB; Bedigian MP; Greig G; Milosavljev S; Skerjanec A; Wang Y
J Clin Pharmacol; 2005 Sep; 45(9):1038-47. PubMed ID: 16100298
[TBL] [Abstract][Full Text] [Related]
40. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
